Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
11/17/20 Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
11/09/20 Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
10/29/20 Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
10/29/20 Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
10/22/20 Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results
Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Quarterly report which provides a continuing view of a company's financial position

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities